<?xml version="1.0"?>
<rss version="2.0">
   <channel>
      <title>Alemtuzumab by Emily Bhagwatprasad</title>
      <link>https://padlet.com/e_bhagwatprasad/iib61svj6mfx</link>
      <description></description>
      <language>en-us</language>
      <pubDate>2018-11-19 21:59:12 UTC</pubDate>
      <lastBuildDate>2026-01-24 16:43:17 UTC</lastBuildDate>
      <webMaster>hello@padlet.com</webMaster>
      <image>
         <url>https://padlet-assets.s3.amazonaws.com/icons/File.png</url>
      </image>
      <item>
         <title>What is it?</title>
         <author>e_bhagwatprasad</author>
         <link>https://padlet.com/e_bhagwatprasad/iib61svj6mfx/wish/306135124</link>
         <description><![CDATA[<div>This product is a drug made with CD52 monoclonal antibodies used for B-cell chronic lymphocytic leukemia.<sup> 1</sup></div>]]></description>
         <enclosure url="" />
         <pubDate>2018-11-19 22:02:13 UTC</pubDate>
         <guid>https://padlet.com/e_bhagwatprasad/iib61svj6mfx/wish/306135124</guid>
      </item>
      <item>
         <title>Needs Statement</title>
         <author>e_bhagwatprasad</author>
         <link>https://padlet.com/e_bhagwatprasad/iib61svj6mfx/wish/306151385</link>
         <description><![CDATA[<div>A way to control the number of cancer cells in patients with chronic lymphocytic leukemia<br><br>About 21,000 new cases were diagnosed this year.<sup>3</sup></div>]]></description>
         <enclosure url="" />
         <pubDate>2018-11-19 23:20:25 UTC</pubDate>
         <guid>https://padlet.com/e_bhagwatprasad/iib61svj6mfx/wish/306151385</guid>
      </item>
      <item>
         <title>How does it work?</title>
         <author>e_bhagwatprasad</author>
         <link>https://padlet.com/e_bhagwatprasad/iib61svj6mfx/wish/306152416</link>
         <description><![CDATA[<div>This drug works by targeting cells expressing significant levels of CD52 found on malignant lymphocytes by mediating lysis. The antibodies attach to the CD52 antigen so it can be detected by the immune system.<sup>2</sup></div>]]></description>
         <enclosure url="http://www.curemycase.com/wp-content/uploads/2017/02/leukemia-treatment.jpg" />
         <pubDate>2018-11-19 23:27:29 UTC</pubDate>
         <guid>https://padlet.com/e_bhagwatprasad/iib61svj6mfx/wish/306152416</guid>
      </item>
      <item>
         <title></title>
         <author>e_bhagwatprasad</author>
         <link>https://padlet.com/e_bhagwatprasad/iib61svj6mfx/wish/306157849</link>
         <description><![CDATA[<div>There does not appear to be ethical issues in using alemtuzumab for treating leukemia, but it has faced challenges as a treatment for multiple sclerosis regarding trials including children<sup>5</sup>.</div>]]></description>
         <enclosure url="" />
         <pubDate>2018-11-20 00:06:24 UTC</pubDate>
         <guid>https://padlet.com/e_bhagwatprasad/iib61svj6mfx/wish/306157849</guid>
      </item>
      <item>
         <title></title>
         <author>e_bhagwatprasad</author>
         <link>https://padlet.com/e_bhagwatprasad/iib61svj6mfx/wish/306158361</link>
         <description><![CDATA[<ol><li><a href="http://chemocare.com/chemotherapy/drug-info/alemtuzumab.aspx">http://chemocare.com/chemotherapy/drug-info/alemtuzumab.aspx</a></li><li><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2767316/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2767316/</a></li><li><a href="https://www.cancer.org/cancer/chronic-lymphocytic-leukemia/about.html">https://www.cancer.org/cancer/chronic-lymphocytic-leukemia/about.html</a></li><li><a href="http://www.whatisbiotechnology.org/index.php/exhibitions/campath/scaling">http://www.whatisbiotechnology.org/index.php/exhibitions/campath/scaling</a></li><li><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3349081/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3349081/</a></li></ol>]]></description>
         <enclosure url="" />
         <pubDate>2018-11-20 00:10:51 UTC</pubDate>
         <guid>https://padlet.com/e_bhagwatprasad/iib61svj6mfx/wish/306158361</guid>
      </item>
      <item>
         <title>Regulatory Process</title>
         <author>e_bhagwatprasad</author>
         <link>https://padlet.com/e_bhagwatprasad/iib61svj6mfx/wish/307574290</link>
         <description><![CDATA[<div>Regulatory approval was granted by the FDA  and the European Medicines Agency<sup>4 <br></sup>Clincal trials have been performed in order to find out the lowest possible effective dose needed for patients </div>]]></description>
         <enclosure url="" />
         <pubDate>2018-11-25 22:20:04 UTC</pubDate>
         <guid>https://padlet.com/e_bhagwatprasad/iib61svj6mfx/wish/307574290</guid>
      </item>
      <item>
         <title>Development </title>
         <author>e_bhagwatprasad</author>
         <link>https://padlet.com/e_bhagwatprasad/iib61svj6mfx/wish/307574973</link>
         <description><![CDATA[<div>Monoclonal antibodies need to be produced, typically using mice, and purified using column chromatography. Following this they are washed with the target molecule, separated into vials and distributed<sup>4</sup>.</div>]]></description>
         <enclosure url="https://www.thermofisher.com/content/dam/LifeTech/global/life-sciences/protein-biology/PBLC/protein_purification_update.jpg" />
         <pubDate>2018-11-25 22:25:40 UTC</pubDate>
         <guid>https://padlet.com/e_bhagwatprasad/iib61svj6mfx/wish/307574973</guid>
      </item>
      <item>
         <title>Market</title>
         <author>e_bhagwatprasad</author>
         <link>https://padlet.com/e_bhagwatprasad/iib61svj6mfx/wish/307577228</link>
         <description><![CDATA[<div>Primary consumers for this product include hospitals and clinics that treat patients with chronic lymphocytic leukemia. </div>]]></description>
         <enclosure url="" />
         <pubDate>2018-11-25 22:41:54 UTC</pubDate>
         <guid>https://padlet.com/e_bhagwatprasad/iib61svj6mfx/wish/307577228</guid>
      </item>
   </channel>
</rss>
